Antibody drug conjugates as cancer therapeutics

Antibodies

Volumn 2, Issue 1, 2013, Pages 113-129

  Trail, Pamela A ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

ADC; Antibody; Antibody drug conjugate; Cancer; Cytotoxic; Drug delivery; Immunoconjugate

Indexed keywords

AGS 5ME; ANTIBODY DRUG CONJUGATE; ASG 22ME; BAY 794620; BAY 949343; BMS 182248; BR96 DOXORUBICIN; BRENTUXIMAB VEDOTIN; BT 062; DCDT 2980S; DOXORUBICIN; DUOCARMYCIN DERIVATIVE; FIRTECAN; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; INOTUZUMAB OZOGAMICIN; LABETUZUMAB; LORVOTUZUMAB MERTANSINE; MDX 1203; METHOTREXATE; MILATUZUMAB; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY; RG 7593; RG 7596; SAR 3419; SAR 566658; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VORSETUZUMAB MAFODOTIN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CELL; CANCER THERAPY; DIARRHEA; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; FATIGUE; FEVER; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA;

EID: 85136070741     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib2010113     Document Type: Review

References (79)

1. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
2. Carter, P. J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6, 343-357.
3. Jakobovits, A. The long-awaited magic bullets: Therapeutic human monoclonal antibodies from transgenic mice. Expert Opin. Investig. Drugs 1998, 7, 607-614.
4. Lonberg, N. Human antibodies from transgenic animals. Nat. Biotechnol. 2005, 23, 1117-1125.
5. Reichert, J. M.; Dhimolea, E. The future of antibodies as cancer drugs. Drug Discov. Today 2012, 17, 954-963.
6. Goldenberg, D. M.; Sharkey, R. M. Radioactive antibodies: A historical review of selective targeting and treatment of cancer. Hosp. Pract. (Minneap) 2010, 38, 82-93.
7. Steiner, M.; Neri, D. Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends. Clin. Cancer Res. 2011, 17, 6406-6416.
8. Weldon, J. E.; Pastan, I. A guide to taming a toxin-Recombinant immunotoxins constructed from pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011, 278, 4683-4700.
9. Lorberboum-Galski, H. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin. Drug Deliv. 2011, 8, 605-621.
10. Choudhary, S.; Mathew, M.; Verma, R. S. Therapeutic potential of anticancer immunotoxins. Drug Discov. Today 2011, 16, 495-503.
11. Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellstrom, I.; Hellstrom, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261, 212-215.
12. Hinman, L. M.; Hamann, P. R.; Wallace, R.; Menendez, A. T.; Durr, F. E.; Upeslacis, J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics. Cancer Res. 1993, 53, 3336-3342.
13. Liu, C.; Chari, R. V. The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin. Investig. Drugs 1997, 6, 169-172.
14. Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Chace, D. F.; DeBlanc, R. L.; Gearing, R. P.; Bovee, T. D.; Siegall, C. B.; et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21, 778-784.
15. Trail, P. A.; Bianchi, A. B. Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 1999, 11, 584-588.
16. Dubowchik, G. M.; Walker, M. A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 1999, 83, 67-123.
17. Dubowchik, G. M.; Firestone, R. A.; Padilla, L.; Willner, D.; Hofstead, S. J.; Mosure, K.; Knipe, J. O.; Lasch, S. J.; Trail, P. A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 2002, 13, 855-869.
18. Trail, P. A.; King, H. D.; Dubowchik, G. M. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol. Immunother. 2003, 52, 328-337.
19. Teicher, B. A. Antibody-drug conjugate targets. Curr. Cancer Drug Targets 2009, 9, 982-1004.
20. Blanc, V.; Bousseau, A.; Caron, A.; Carrez, C.; Lutz, R. J.; Lambert, J. M. SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin. Cancer Res. 2011, 17, 6448-6458.
21. Lewis Phillips, G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Blattler, W. A.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68, 9280-9290.
22. Petrul, H. M.; Schatz, C. A.; Kopitz, C. C.; Adnane, L.; McCabe, T. J.; Trail, P.; Ha, S.; Chang, Y. S.; Voznesensky, A.; Ranges, G.; et al. Therapeutic mechanism and efficacy of the antibodydrug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol. Cancer Ther. 2012, 11, 340-349.
23. Wahl, A. F.; Klussman, K.; Thompson, J. D.; Chen, J. H.; Francisco, L. V.; Risdon, G.; Chace, D. F.; Siegall, C. B.; Francisco, J. A. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002, 62, 3736-3742.
24. Barginear, M. F.; John, V.; Budman, D. R. Trastuzumab-DM1: A clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol. Med. 2012, 18, 1473-1479.
25. Ogura, M.; Hatake, K.; Ando, K.; Tobinai, K.; Tokushige, K.; Ono, C.; Ishibashi, T.; Vandendries, E. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012, 103, 933-938.
26. Ricart, A. D. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 2011, 17, 6417-6427.
27. Verma, S.; Miles, D.; Gianni, L.; Krop, I. E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D. Y.; Dieras, V.; Guardino, E.; et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367, 1783-1791.
28. Younes, A.; Bartlett, N. L.; Leonard, J. P.; Kennedy, D. A.; Lynch, C. M.; Sievers, E. L.; Forero-Torres, A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 2010, 363, 1812-1821.
29. Younes, A.; Kim, S.; Romaguera, J.; Copeland, A.; Farial Sde, C.; Kwak, L. W.; Fayad, L.; Hagemeister, F.; Fanale, M.; Neelapu, S.; et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J. Clin. Oncol. 2012, 30, 2776-2782.
30. Gerber, H. P.; Senter, P. D.; Grewal, I. S. Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. MAbs 2009, 1, 247-253.
31. Baccala, A.; Sercia, L.; Li, J.; Heston, W.; Zhou, M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007, 70, 385-390.
32. Haffner, M. C.; Kronberger, I. E.; Ross, J. S.; Sheehan, C. E.; Zitt, M.; Muhlmann, G.; Ofner, D.; Zelger, B.; Ensinger, C.; Yang, X. J.; et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol. 2009, 40, 1754-1761.
33. Denmeade, S. R.; Mhaka, A. M.; Rosen, D. M.; Brennen, W. N.; Dalrymple, S.; Dach, I.; Olesen, C.; Gurel, B.; Demarzo, A. M.; Wilding, G.; et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci. Transl. Med. 2012, 4, 140ra86.
34. Katz, J.; Janik, J. E.; Younes, A. Brentuximab vedotin (SGN-35). Clin. Cancer Res. 2011, 17, 6428-6436.
35. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Lutz, R. J.; Yasui, H.; Okawa, Y.; Kiziltepe, T.; Vallet, S.; Pozzi, S.; Santo, L.; et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 2009, 15, 4028-4037.
36. DeFrancesco, L. Seattle genetics rare cancer drug sails through accelerated approval. Nat. Biotechnol. 2011, 29, 851-852.
37. Jiang, X. R.; Song, A.; Bergelson, S.; Arroll, T.; Parekh, B.; May, K.; Chung, S.; Strouse, R.; Mire-Sluis, A.; Schenerman, M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 2011, 10, 101-111.
38. Junttila, T. T.; Li, G.; Parsons, K.; Phillips, G. L.; Sliwkowski, M. X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 2011, 128, 347-356.
39. Kovtun, Y. V.; Goldmacher, V. S. Cell killing by antibody-drug conjugates. Cancer Lett. 2007, 255, 232-240.
40. Okeley, N. M.; Miyamoto, J. B.; Zhang, X.; Sanderson, R. J.; Benjamin, D. R.; Sievers, E. L.; Senter, P. D.; Alley, S. C. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 2010, 16, 888-897.
41. Chari, R. V. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc. Chem. Res. 2008, 41, 98-107.
42. Doronina, S. O.; Bovee, T. D.; Meyer, D. W.; Miyamoto, J. B.; Anderson, M. E.; Morris-Tilden, C. A.; Senter, P. D. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug. Chem. 2008, 19, 1960-1963.
43. Dubowchik, G. M.; Radia, S.; Mastalerz, H.; Walker, M. A.; Firestone, R. A.; Dalton King, H.; Hofstead, S. J.; Willner, D.; Lasch, S. J.; Trail, P. A. Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages. Bioorg. Med. Chem. Lett. 2002, 12, 1529-1532.
44. Zhao, R. Y.; Wilhelm, S. D.; Audette, C.; Jones, G.; Leece, B. A.; Lazar, A. C.; Goldmacher, V. S.; Singh, R.; Kovtun, Y.; Widdison, W. C.; et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J. Med. Chem. 2011, 54, 3606-3623.
45. Smyth, M. J.; Pietersz, G. A.; McKenzie, I. F. The mode of action of methotrexate-monoclonal antibody conjugates. Immunol. Cell Biol. 1987, 65, 189-200.
46. Ghose, T.; Ferrone, S.; Blair, A. H.; Kralovec, Y.; Temponi, M.; Singh, M.; Mammen, M. Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225. 28 to human high molecular weight-melanoma associated antigen. Cancer Immunol. Immunother. 1991, 34, 90-96.
47. Elias, D. J.; Kline, L. E.; Robbins, B. A.; Johnson, H. C., Jr.; Pekny, K.; Benz, M.; Robb, J. A.; Walker, L. E.; Kosty, M.; Dillman, R. O. Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am. J. Respir. Crit. Care Med. 1994, 150, 1114-1122.
48. Schrappe, M.; Bumol, T. F.; Apelgren, L. D.; Briggs, S. L.; Koppel, G. A.; Markowitz, D. D.; Mueller, B. M.; Reisfeld, R. A. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9. 2. 27. Cancer Res. 1992, 52, 3838-3844.
49. Petersen, B. H.; DeHerdt, S. V.; Schneck, D. W.; Bumol, T. F. The human immune response to KS1/4-desacetylvinblastine (ly256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 1991, 51, 2286-2290.
50. Yang, H. M.; Reisfeld, R. A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA 1988, 85, 1189-1193.
51. Shih, L. B.; Goldenberg, D. M.; Xuan, H.; Lu, H. W.; Mattes, M. J.; Hall, T. C. Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol. Immunother. 1994, 38, 92-98.
52. Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Greenfield, R. S.; King, D.; Zoeckler, M. E.; Braslawsky, G. R. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res. 1992, 52, 5693-5700.
53. King, H. D.; Yurgaitis, D.; Willner, D.; Firestone, R. A.; Yang, M. B.; Lasch, S. J.; Hellstrom, K. E.; Trail, P. A. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. Bioconjug. Chem. 1999, 10, 279-288.
54. King, H. D.; Dubowchik, G. M.; Mastalerz, H.; Willner, D.; Hofstead, S. J.; Firestone, R. A.; Lasch, S. J.; Trail, P. A. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains. J. Med. Chem. 2002, 45, 4336-4343.
55. Shih, L. B.; Goldenberg, D. M.; Xuan, H.; Lu, H.; Sharkey, R. M.; Hall, T. C. Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier. Cancer Res. 1991, 51, 4192-4198.
56. Saleh, M. N.; LoBuglio, A. F.; Trail, P. A. Immunoconjugate Therapy of Solid Tumors: Studies with BR96-Doxorubicin. In Monoclonal Antibody-Based Therapy of Cancer, 1st ed.; Grossbard, M. L., Ed.; Marcel Dekker, Inc: New York, NY, USA, 1998; Volume 15, pp. 397-416.
57. Terrett, J.; Gangwar, S.; Rao-Naik, C.; Pan, C.; Guerlavais, V.; Huber, M.; Chong, C.; Green, L.; Cardarelli, P.; King, D.; et al. Single, low dose treatment of lymphoma and renal cancer xenografts with human anti-CD70 antibody-toxin conjugates, results in long term cures. In Proceedings of the 98th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, USA, 14-18 April 2007.
58. Bross, P. F.; Beitz, J.; Chen, G.; Chen, X. H.; Duffy, E.; Kieffer, L.; Roy, S.; Sridhara, R.; Rahman, A.; Williams, G.; et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7, 1490-1496.
59. Larson, R. A.; Sievers, E. L.; Stadtmauer, E. A.; Lowenberg, B.; Estey, E. H.; Dombret, H.; Theobald, M.; Voliotis, D.; Bennett, J. M.; Richie, M.; et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104, 1442-1452.
60. Jurcic, J. G. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr. Hematol. Malig. Rep. 2012, 7, 65-73.
61. DiJoseph, J. F.; Dougher, M. M.; Evans, D. Y.; Zhou, B. B.; Damle, N. K. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother. Pharmacol. 2011, 67, 741-749.
62. Advani, A.; Coiffier, B.; Czuczman, M. S.; Dreyling, M.; Foran, J.; Gine, E.; Gisselbrecht, C.; Ketterer, N.; Nasta, S.; Rohatiner, A.; et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a phase I study. J. Clin. Oncol. 2010, 28, 2085-2093.
63. Cardarelli, P.; King, D.; Terrett, J.; Gangwar, S.; Cohen, L.; Pan, C.; Rao, C.; Deshpande, S.; angipuram, R.; Passmore, D.; et al. Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate. In Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 12-16 April 2008; AACR: Philadelphia, PA, USA, 2008; Abstract nr 4061.
64. King, D.; Terrett, J.; Cardarelli, P.; Pan, C.; Rao, C.; Gangwar, S.; Deshpande, S.; Vangipuram, R.; Passmore, D.; Mirjolet, J.; et al. Mechanism of activation of a human anti-CD70 antibodymgba conjugate and efficacy in a nude rat model of renal carcinoma. In Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 12-16 April 2008; AACR: Philadelphia, PA, USA, 2008; Abstract nr 4057.
65. Beck, A.; Lambert, J.; Sun, M.; Lin, K. Fourth World Antibody-drug Conjugate Summit: February 29-march 1, 2012, Frankfurt, Germany. MAbs 2012, 4, 637-647.
66. Chari, R. V.; Martell, B. A.; Gross, J. L.; Cook, S. B.; Shah, S. A.; Blattler, W. A.; McKenzie, S. J.; Goldmacher, V. S. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res. 1992, 52, 127-131.
67. Oroudjev, E.; Lopus, M.; Wilson, L.; Audette, C.; Provenzano, C.; Erickson, H.; Kovtun, Y.; Chari, R.; Jordan, M. A. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther. 2010, 9, 2700-2713.
68. Mohammad, R. M.; Varterasian, M. L.; Almatchy, V. P.; Hannoudi, G. N.; Pettit, G. R.; Al-Katib, A. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Clin. Cancer Res. 1998, 4, 1337-1343.
69. Doronina, S. O.; Mendelsohn, B. A.; Bovee, T. D.; Cerveny, C. G.; Alley, S. C.; Meyer, D. L.; Oflazoglu, E.; Toki, B. E.; Sanderson, R. J.; Zabinski, R. F.; et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 2006, 17, 114-124.
70. Francisco, J. A.; Cerveny, C. G.; Meyer, D. L.; Mixan, B. J.; Klussman, K.; Chace, D. F.; Rejniak, S. X.; Gordon, K. A.; DeBlanc, R.; Toki, B. E.; et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102, 1458-1465.
71. Widdison, W. C.; Wilhelm, S. D.; Cavanagh, E. E.; Whiteman, K. R.; Leece, B. A.; Kovtun, Y.; Goldmacher, V. S.; Xie, H.; Steeves, R. M.; Lutz, R. J.; et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49, 4392-4408.
72. de Claro, R. A.; McGinn, K.; Kwitkowski, V.; Bullock, J.; Khandelwal, A.; Habtemariam, B.; Ouyang, Y.; Saber, H.; Lee, K.; Koti, K.; et al. U. S. Food and drug administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin. Cancer Res. 2012, 18, 5845-5849.
73. Jackson, D.; Gooya, J.; Mao, S.; Kinneer, K.; Xu, L.; Camara, M.; Fazenbaker, C.; Fleming, R.; Swamynathan, S.; Meyer, D.; et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 2008, 68, 9367-9374.
74. Oflazoglu, E.; Stone, I. J.; Gordon, K.; Wood, C. G.; Repasky, E. A.; Grewal, I. S.; Law, C. L.; Gerber, H. P. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin. Cancer Res. 2008, 14, 6171-6180.
75. Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M.; et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365, 1273-1283.
76. Younes, A.; Yasothan, U.; Kirkpatrick, P. Brentuximab vedotin. Nat. Rev. Drug Discov. 2012, 11, 19-20.
77. Hartley, J. A.; Hochhauser, D. Small molecule drugs-optimizing DNA damaging agent-based therapeutics. Curr. Opin. Pharmacol. 2012, 12, 398-402.
78. Junutula, J. R.; Flagella, K. M.; Graham, R. A.; Parsons, K. L.; Ha, E.; Raab, H.; Bhakta, S.; Nguyen, T.; Dugger, D. L.; Li, G.; et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res. 2010, 16, 4769-4778.
79. Sapra, P.; Hooper, A. T.; O'Donnell, C. J.; Gerber, H. P. Investigational antibody drug conjugates for solid tumors. Expert Opin. Investig. Drugs 2011, 20, 1131-1149.